Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by New York Life Investment Management LLC

New York Life Investment Management LLC lessened its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 14.4% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 54,873 shares of the medical research company's stock after selling 9,227 shares during the quarter. New York Life Investment Management LLC's holdings in Thermo Fisher Scientific were worth $29,126,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of the business. Vanguard Group Inc. grew its stake in Thermo Fisher Scientific by 0.6% during the 3rd quarter. Vanguard Group Inc. now owns 32,760,738 shares of the medical research company's stock valued at $16,582,503,000 after purchasing an additional 180,618 shares in the last quarter. Morgan Stanley grew its stake in Thermo Fisher Scientific by 0.4% during the 3rd quarter. Morgan Stanley now owns 12,418,429 shares of the medical research company's stock valued at $6,285,838,000 after purchasing an additional 50,736 shares in the last quarter. Northern Trust Corp grew its stake in Thermo Fisher Scientific by 2.6% during the 3rd quarter. Northern Trust Corp now owns 3,929,225 shares of the medical research company's stock valued at $1,988,856,000 after purchasing an additional 99,377 shares in the last quarter. Wellington Management Group LLP grew its stake in Thermo Fisher Scientific by 9.8% during the 3rd quarter. Wellington Management Group LLP now owns 3,080,687 shares of the medical research company's stock valued at $1,559,351,000 after purchasing an additional 274,464 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in shares of Thermo Fisher Scientific by 0.4% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,184,928 shares of the medical research company's stock worth $1,105,945,000 after acquiring an additional 8,672 shares in the last quarter. Institutional investors and hedge funds own 89.23% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. Citigroup assumed coverage on Thermo Fisher Scientific in a research report on Monday, March 18th. They issued a "neutral" rating and a $620.00 target price for the company. Evercore ISI lifted their target price on Thermo Fisher Scientific from $575.00 to $610.00 and gave the stock an "outperform" rating in a research report on Thursday, April 4th. Raymond James raised their price target on Thermo Fisher Scientific from $515.00 to $605.00 and gave the stock an "outperform" rating in a report on Thursday, February 1st. Deutsche Bank Aktiengesellschaft raised their price target on Thermo Fisher Scientific from $600.00 to $610.00 and gave the stock a "buy" rating in a report on Thursday, April 25th. Finally, JPMorgan Chase & Co. raised their price target on Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an "overweight" rating in a report on Thursday, April 25th. Five investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $607.35.

Thermo Fisher Scientific Price Performance

Shares of TMO stock traded up $6.27 during mid-day trading on Wednesday, hitting $574.99. 1,171,929 shares of the stock traded hands, compared to its average volume of 1,549,559. Thermo Fisher Scientific Inc. has a twelve month low of $415.60 and a twelve month high of $603.82. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.33 and a current ratio of 1.70. The firm has a market cap of $219.48 billion, a price-to-earnings ratio of 36.48, a price-to-earnings-growth ratio of 2.40 and a beta of 0.80. The company's 50-day simple moving average is $574.58 and its 200-day simple moving average is $531.67.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings data on Wednesday, April 24th. The medical research company reported $5.11 earnings per share for the quarter, beating the consensus estimate of $4.70 by $0.41. The company had revenue of $10.35 billion for the quarter, compared to analyst estimates of $10.14 billion. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. As a group, equities research analysts expect that Thermo Fisher Scientific Inc. will post 21.59 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, April 15th. Shareholders of record on Friday, March 15th were issued a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a yield of 0.27%. The ex-dividend date of this dividend was Thursday, March 14th. This is a boost from Thermo Fisher Scientific's previous quarterly dividend of $0.35. Thermo Fisher Scientific's dividend payout ratio is 10.01%.

Insiders Place Their Bets

In related news, CEO Marc N. Casper sold 10,000 shares of the firm's stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $597.98, for a total value of $5,979,800.00. Following the completion of the sale, the chief executive officer now directly owns 123,816 shares in the company, valued at approximately $74,039,491.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 2,000 shares of the business's stock in a transaction on Friday, April 26th. The shares were sold at an average price of $567.94, for a total transaction of $1,135,880.00. Following the sale, the senior vice president now owns 13,083 shares of the company's stock, valued at $7,430,359.02. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $597.98, for a total transaction of $5,979,800.00. Following the transaction, the chief executive officer now owns 123,816 shares in the company, valued at approximately $74,039,491.68. The disclosure for this sale can be found here. In the last 90 days, insiders sold 62,277 shares of company stock worth $35,373,364. Corporate insiders own 0.34% of the company's stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.